自发性家禽疫苗的基因组定制,以减少从农场到餐桌的坎皮洛巴克特菌
相关实验视频
Updated: May 31, 2026

08:26
Nucleofection and In Vivo Propagation of Chicken Eimeria Parasites
Published on: February 14, 2020
6.9K
Jessica K Calland1, Maiju E Pesonen2, Jai Mehat3
1Oslo Centre for Biostatistics and Epidemiology, Oslo University Hospital, Oslo, Norway. jessica.calland@medisin.uio.no.
NPJ vaccines
|June 12, 2024
概括
一种新的家禽疫苗通过向特定的生存基因,显著减少了有害的坎皮洛巴克特菌株. 这种方法提供了一个有前途的战略,以提高食品安全和减少食源性疾病.
科学领域:
- 食品安全 食品安全
- 兽医微生物学 兽医微生物学
- 基因组学就是基因组学.
背景情况:
- 坎比洛巴克是全球性食源性胃肠炎的主要原因,主要来自受污染的家禽.
- 目前的家禽疫苗只能提供短期的减肥效果,并且未能解决菌株的多样性和进化问题.
- 现有的疫苗并不能有效地减少食物链中的坎皮洛巴克特菌或人类的发病率.
研究的目的:
- 使用基因组方法开发全细胞自身疫苗,以向具有增强生存基因的坎皮洛巴克特菌株.
- 通过来自超免疫养殖场的母性衍生抗体被动免疫肉后代.
- 评估疫苗对和肉表面的坎皮洛巴克特菌种群的影响.
主要方法:
- 基因组分析以识别具有肠外生存基因的坎皮洛巴克特分离物.
- 开发一种针对这些特定基因的全细胞自身疫苗.
- 一个育种场的超级免疫,以诱导后代产生来自母亲的抗体.
- 疫苗接种后对肉群和肉表面的坎皮洛巴克特菌种群的监测.
主要成果:
- 接种疫苗后观察到坎皮洛巴克特菌种群的显著转变.
- 在携带肠外生存基因的坎皮洛巴克特分离物中实现了~50%的减少.
- 有证据表明,Campylobacter在肉表面的存活率显著降低.
- 一种后勤回归模型预测了针对65%临床相关菌株的潜在疫苗疗效.
结论:
- 开发的自身疫苗有效地减少了家禽中向的坎皮洛巴克特菌株.
- 孕产妇产生的抗体提供了一种可行的方法,用于对坎皮洛巴克特的被动免疫.
- 针对特定的生存基因和利用基因组方法显示出改善食物链安全的前景.
- 禽类微生物组的免疫操纵具有在食品生产中减少病原体的巨大潜力.
相关概念视频
The Central Dogma
The central dogma explains the flow of genetic information from DNA nucleotides to the amino acid sequence of proteins.
RNA is the Missing Link Between DNA and Proteins
In the early 1900s, scientists discovered that DNA stores all the information needed for cellular functions and that proteins perform most of these functions. However, the mechanisms of converting genetic information into functional proteins remained unknown for many years. Initially, it was believed that a single gene is...
RNA is the Missing Link Between DNA and Proteins
In the early 1900s, scientists discovered that DNA stores all the information needed for cellular functions and that proteins perform most of these functions. However, the mechanisms of converting genetic information into functional proteins remained unknown for many years. Initially, it was believed that a single gene is...
Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...

